In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UCB Group

www.ucb-group.com

Latest From UCB Group

FTC Closer To Clearing Roche's Spark Buy: Report

Capitol Forum reports that FTC staff have recommended the proposed acquisition of Spark by Roche be approved without requiring any asset sales. The end could be in sight for the long-drawn out affair.

M & A Legal Issues

Evenity Gets CHMP Nod On Second Pass

UCB and Amgen’s osteoporosis drug Evenity has been given a positive opinion in Europe after initial rejection. But cardiovascular safety concerns and rival products constrain sales potential.

Approvals Europe

Interview: Akari's Coversin Ticking Along Nicely

The C5 complement inhibitor class is in the news following UCB's bid for Ra Pharmaceuticals. Akari's CEO tells Scrip he thinks Coversin, which inhibits leukotriene B4 as well as C5, may offer more benefits in certain orphan diseases.

Rare Diseases Inflammation

UCB To Buy Ra for $2.1bn And Plays Down Antitrust Fears

The deal, welcomed by analysts, means that the Belgian drug maker has two late-stage products for the rare disease myasthenia gravis to challenge Alexion's Soliris.
M & A Companies
See All

Company Information

UsernamePublicRestriction

Register